The chronic treatment of AZP2006 attenuates the cognitive impairments and neuronal synaptic damage, accompanied by significant decreases in microglial activation, proinflammatory cytokine release, and tau hyperphosphorylation in the brains of AD and aging model mice. The gene discussed is MAPT; the disease is Alzheimer disease.